fish tank NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Ready Capital Corporation (NYSE: RC) (“Ready Capital” or the “Company”) today announced that it closed an underwritten public offering of $130 million aggregate principal amount of 9.00% Senior Notes due 2029 (the “Notes”), including $15 million aggregate principal amount relating to the partial exercise of the underwriters’ over-allotment option. The Notes were issued in minimum denominations and integral multiples of $25.00. The Company intends to use the net proceeds from this offering to originate or acquire target assets consistent with its investment strategy and for general corporate purposes. Morgan Stanley & Co. LLC, Piper Sandler & Co., RBC Capital Markets, LLC, UBS Investment Bank and Wells Fargo Securities, LLC served as book-running managers for the offering. The Notes have been approved for listing on the New York Stock Exchange under the symbol “RCD” and trading is expected to commence within 30 days of the closing of the offering. A registration statement relating to the securities was filed with the Securities and Exchange Commission (the “SEC”) and immediately became effective on March 22, 2022. The offering was made only by means of a prospectus supplement and accompanying prospectus, which have been filed with the SEC. A copy of the prospectus supplement and accompanying prospectus may be obtained free of charge at the SEC’s website at www.sec.gov or from the underwriters by contacting: Morgan Stanley & Co. LLC by calling 1-800-584-6837, Piper Sandler & Co. at 1251 Avenue of the Americas, 6th Floor, New York, NY 10020, or by calling toll-free 866-805-4128, or by email at fsg-dcm@psc.com , RBC Capital Markets, LLC by calling 1-866-375-6829 or by emailing rbcnyfixedincomeprospectus@rbccm.com , UBS Investment Bank by calling 1-888-827-7275, Wells Fargo Securities, LLC by calling 1-800-645-3751 or by emailing wfscustomerservice@wellsfargo.com . This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the Company’s securities, nor shall there be any sale of the Company’s securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. About Ready Capital Corporation Ready Capital Corporation (NYSE: RC) is a multi-strategy real estate finance company that originates, acquires, finances and services lower-to-middle-market investor and owner occupied commercial real estate loans. Ready Capital specializes in loans backed by commercial real estate, including agency multifamily, investor, construction, and bridge as well as U.S. Small Business Administration loans under its Section 7(a) program. Headquartered in New York, New York, Ready Capital employs approximately 350 professionals nationwide. Ready Capital is externally managed and advised by Waterfall Asset Management, LLC. Forward-Looking Statements This press release contains certain forward-looking statements. Words such as “believe,” “expect,” “anticipate,” “estimate,” “plan,” “continue,” “intend,” “should,” “could,” “would,” “may,” “potential” or the negative of those terms or other comparable terminology are intended to identify forward-looking statements. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions, many of which are beyond the control of the Company, including, without limitation, the risk factors and other matters set forth in the prospectus supplement and the accompanying prospectus and the Company’s Annual Report on Form 10–K for the year ended December 31, 2023 filed with the SEC and in its other filings with the SEC. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. Contacts: Investor Relations Ready Capital Corporation 212-257-4666 InvestorRelations@readycapital.comNo. 2 UConn falls again in Maui, losing 73-72 to Colorado on Jakimovski's off-balance layupNone

Houston Texans wide receiver Nico Collins scored a touchdown against the Tennessee Titans in his most recent home game and tossed the ball to a child in the stands pleading for it. On Thursday, Collins told reporters the NFL did not approve and assessed him a fine of about $5,000. "It's for the kids," Collins said. "I seen he was screaming and was thinking, ‘Here you go, big dog. Here's the ball.'" Collins said he was not penalized last season on the handful of occasions he threw a ball into the stands, so he wasn't expecting a fine. But making a child's day was "definitely worth it." The 25-year-old said he plans to appeal the fine, but if it isn't overturned, he'll pay up. "The only thing that matters was making that kid happy," he said. "He ain't never going to forget that moment. So that's all that matters to me." Collins followed up a 92-yard, one-touchdown performance that day against Tennessee with eight receptions for 119 yards last week at Jacksonville. The fourth-year wideout is Houston's leading receiver despite missing five games due to a hamstring injury. He has caught 49 passes for 832 yards and four touchdowns in just eight appearances. --Field Level Media

DK Metcalf is happy to block as Seahawks ride streak into Sunday night matchup with Packers

Guest Opinion: The fights over culturally divisive issues in schools? They cost billions that could be spent helping kidsThe Cannabist Company Launches dreamt Brand, to Maryland Market

TEANECK, N.J. , Nov. 22, 2024 /PRNewswire/ -- GC Biopharma USA , the commercial operations and distribution company of GC Biopharma, has announced the appointment of industry veteran, Sean Zam , to its senior leadership team as Head of Sales and Marketing. He comes to GC Biopharma USA with a wealth of experience in the pharmaceutical industry, including extensive experience in plasma therapeutics. Sean has a proven track record of growing business and building lasting partnerships for companies such as Grifols, AstraZeneca, and Pfizer. Lisa Betts , Chief Operating Officer at GC Biopharma USA , says the following about Sean: "He's everything we'd hoped to find in a sales and marketing leader. He's authentic, earnest, experienced, and passionate about the IG industry. His core values align perfectly with the unique leadership team we are building." Sean shares his excitement: "When I joined the GC Biopharma USA leadership team, I was inspired by how differently they approach the business. It's not just about business; it's about relationships and the communities they serve. It was something I knew I wanted to be a part of." He adds: "I'm always struck by the strength and resourcefulness of patients who take the initiative to find answers, especially those living with rare diseases. It propels me to push harder. That's partly why I joined this growing team. It's a great opportunity to have a real impact." Sean Zam's appointment further contributes to GC's vision of establishing excellence within its US-based operations. About GC Biopharma GC Biopharma USA , headquartered in Teaneck, NJ , established its sales, marketing, and business operations in 2018 to serve customers and patients throughout the US. Our foundation is built on the expertise of our parent company GC Biopharma, a leading biopharmaceutical company delivering plasma therapies and vaccines worldwide for more than 50 years. With GC Biopharma USA , GC Biopharma will further extend its footprint, bringing its expertise and legacy to the US. This press release may contain forward-looking statements that express the current beliefs and expectations of the management at GC Biopharma and GC Biopharma USA . Such views do not represent any guarantee by either entity or its government of future performance and involve known and unknown risks, uncertainties, and other factors. GC Biopharma and GC Biopharma USA undertake no obligation to update or revise any forward-looking statement contained in this press release or any other forward-looking statements they may make, except as required by law or stock exchange rule. ©2024 GC Biopharma USA , Inc. All rights reserved. All trademarks are the property of their respective owners. ALY-C-0074 11/2024 View original content to download multimedia: https://www.prnewswire.com/news-releases/sean-zam-named-head-of-sales-and-marketing-at-gc-biopharma-usa-302314539.html SOURCE GC Biopharma USA Inc.STATESVILLE, N.C. , Dec. 11, 2024 /PRNewswire/ -- Kewaunee Scientific Corporation KEQU today announced results for its second quarter ended October 31, 2024 . Fiscal Year 2025 Second Quarter Results: Sales during the second quarter of fiscal year 2025 were $47,764,000 , a decrease of 5.3% compared to sales of $50,436,000 from the prior year's second quarter. Pre-tax earnings for the quarter were $3,931,000 compared to $4,845,000 for the prior year quarter, a decrease of 18.9%. Net earnings were $3,008,000 compared to net earnings of $2,732,000 for the prior year quarter. EBITDA 1 for the quarter was $4,883,000 compared to $5,662,000 for the prior year quarter. Diluted earnings per share was $1.01 compared to diluted earnings per share of $0.93 in the prior year quarter. The Company's order backlog was at a historically high level of $184 .4 million on October 31, 2024 , as compared to $146 .3 million on October 31, 2023 , and $155 .6 million on April 30, 2024 . Domestic Segment - Domestic sales for the quarter were $36,409,000 , an increase of 6.5% from sales of $34,185,000 in the prior year quarter. Domestic segment net earnings was $4,524,000 compared to $3,054,000 in the prior year quarter. Domestic segment EBITDA was $6,838,000 compared to $5,230,000 for the prior year quarter. The increase in Domestic sales and earnings was primarily driven by higher product demand. International Segment - International sales for the quarter were $11,355,000 , a decrease of 30.1% from sales of $16,251,000 in the prior year quarter. International segment net earnings was $356,000 compared to $525,000 in the prior year quarter. International segment EBITDA was $592,000 compared to $1,635,000 for the prior year quarter. The decline in sales is attributable to customer construction site delays in India which pushed out the timing of deliveries. Corporate Segment – Corporate segment pre-tax net loss was $2,444,000 for the quarter, as compared to a pre-tax net loss of $1,243,000 in the prior year quarter. Corporate segment EBITDA for the quarter was ($2,547,000) compared to corporate segment EBITDA of ($1,203,000) for the prior year quarter. The change in EBITDA was primarily driven by an increase in professional service and other fees during the quarter related to the acquisition of Nu Aire, Inc., which closed on November 1, 2024 , and costs incurred related to Sarbanes-Oxley 404(b) compliance readiness. Total cash on hand on October 31, 2024 was $29,664,000 , as compared to $25,938,000 on April 30, 2024 . Working capital was $59,965,000 , as compared to $52,144,000 at the end of the second quarter last year and $56,037,000 on April 30, 2024 . The Company had short-term debt of $805,000 as of October 31, 2024 , as compared to $3,099,000 on April 30, 2024 . Long-term debt was $28,047,000 on October 31, 2024 , as compared to $28,479,000 on April 30, 2024 . The building lease from the Company's December 2021 sale-leaseback transaction accounts for $27,782,000 of the long-term debt on October 31, 2024 and $28,133,000 of the long-term debt on April 30, 2024 . Long-term debt, net of the sale-leaseback transaction, was $265,000 on October 31, 2024 as compared to $346,000 on April 30, 2024 . The Company's debt-to-equity ratio on October 31, 2024 was 0.59-to-1, as compared to 0.70-to-1 on April 30, 2024. The Company's debt-to-equity ratio, net of the sale-leaseback transaction, on October 31, 2024 was 0.14-to-1, as compared to 0.20-to-1 on April 30, 2024 . "Our financial performance for the second quarter of fiscal year 2025 was strong," said Thomas D. Hull III , Kewaunee's President and Chief Executive Officer. "Domestic segment operating performance improved compared to last year's second quarter as a result of higher product demand, highlighting our continued health and advantage in the market. As discussed during the first quarter of fiscal year 2025, customer construction site delays in India on multiple projects continue to impact our ability to ship products and deliver services, leading to a decrease in sales and earnings when compared to the prior year second quarter." "Looking ahead, our backlog remains very healthy, demonstrating the continued vitality and investment in the markets in which Kewaunee participates and the success both Kewaunee and our channel partners continue to achieve in the marketplace. The strength of Kewaunee's backlog positions the company well to deliver another strong year for our fiscal year." "Additionally, on November 1, 2024 , Kewaunee announced the acquisition of Nu Aire, Inc.," Hull continued. "Nu Aire is renowned for its manufacturing of robust containment solutions, such as biological safety cabinets, airflow products, and more, which serve a diverse range of industries. While not reflected in our second quarter fiscal year 2025 results, Nu Aire will be included going forward, beginning with our third quarter fiscal year 2025 results. It is worth noting the company incurred expenses related to the acquisition of $2.3 million in the current fiscal year, which are outlined in the attached exhibits." "The acquisition of Nu Aire presents a unique opportunity for Kewaunee to expand its capabilities, allowing the combined organization to better meet the diverse needs of end-users in laboratory furnishings and, through Nu Aire's established distribution partners, reach regions where Kewaunee has not previously had a presence. This move accelerates the Company's vision of becoming the market leader in the design and manufacturing of laboratory furniture and technical products essential for outfitting the laboratories of tomorrow." 1 EBITDA is a non-GAAP financial measure. See the table below for a reconciliation of EBITDA and segment EBITDA to net earnings (loss), the most directly comparable GAAP measure. EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA Reconciliation (Unaudited) ($ in thousands) Quarter Ended October 31, 2023 Domestic International Corporate Consolidated Net Earnings (Loss) $ 3,054 $ 525 $ (847) $ 2,732 Add/(Less): Interest Expense 323 35 14 372 Interest Income — (205) (22) (227) Income Taxes 1,232 1,179 (396) 2,015 Depreciation and Amortization 621 101 48 770 EBITDA $ 5,230 $ 1,635 $ (1,203) $ 5,662 Quarter Ended October 31, 2024 Domestic International Corporate Consolidated Net Earnings (Loss) $ 4,524 $ 356 $ (1,872) $ 3,008 Add/(Less): Interest Expense 413 19 10 442 Interest Income — (133) (156) (289) Income Taxes 1,241 247 (572) 916 Depreciation and Amortization 660 103 43 806 EBITDA $ 6,838 $ 592 $ (2,547) $ 4,883 Professional & Other Fees — — 1,540 2 1,540 Adjusted EBITDA $ 6,838 $ 592 $ (1,007) $ 6,423 Year to Date October 31, 2023 Domestic International Corporate Consolidated Net Earnings (Loss) $ 5,765 $ 994 $ (1,553) $ 5,206 Add/(Less): Interest Expense 703 71 28 802 Interest Income — (418) (23) (441) Income Taxes 2,145 1,461 (694) 2,912 Depreciation and Amortization 1,195 197 96 1,488 EBITDA $ 9,808 $ 2,305 $ (2,146) $ 9,967 Year to Date October 31, 2024 Domestic International Corporate Consolidated Net Earnings (Loss) $ 7,395 $ 819 $ (3,013) $ 5,201 Add/(Less): Interest Expense 854 40 20 914 Interest Income — (307) (329) (636) Income Taxes 2,005 526 (1,423) 1,108 Depreciation and Amortization 1,322 210 89 1,621 EBITDA $ 11,576 $ 1,288 $ (4,656) $ 8,208 Professional & Other Fees — — 2,270 3 2,270 Adjusted EBITDA $ 11,576 $ 1,288 $ (2,386) $ 10,478 ______________________________ 2 Professional and other fees incurred during the three months ended October 31, 2024 related to the Company's acquisition of Nu Aire, Inc. ("Nu Aire"), which closed on November 1, 2024 3 Professional and other fees incurred during the six months ended October 31, 2024 related to the Company's acquisition of Nu Aire Adjusted Consolidated Statement of Operations Reconciliation (Unaudited) ($ in thousands, except per share amounts) Three Months Ended October 31, As Reported 2024 Professional & Other Fees Adjusted 2024 2023 Net sales $ 47,764 $ — $ 47,764 $ 50,436 Cost of products sold 33,812 — 33,812 36,968 Gross profit 13,952 — 13,952 13,468 Operating expenses 9,518 1,216 4 8,302 8,359 Operating profit 4,434 1,216 5,650 5,109 Pension expense — — — (40) Other (expense) income, net (61) 324 5 263 148 Interest expense (442) — (442) (372) Profit before income taxes 3,931 1,540 5,471 4,845 Income tax expense 916 351 6 1,267 2,015 Net earnings 3,015 1,189 4,204 2,830 Less: Net earnings attributable to the non-controlling interest 7 — 7 98 Net earnings attributable to Kewaunee Scientific Corporation $ 3,008 $ 1,189 $ 4,197 $ 2,732 Net earnings per share attributable to Kewaunee Scientific Corporation stockholders Basic $ 1.05 $ 0.41 $ 1.46 $ 0.94 Diluted $ 1.01 $ 0.40 $ 1.41 $ 0.93 Six Months Ended October 31, As Reported 2024 Professional & Other Fees Adjusted 2024 2023 Net sales $ 96,157 $ — $ 96,157 $ 100,275 Cost of products sold 69,717 — 69,717 74,893 Gross profit 26,440 — 26,440 25,382 Operating expenses 19,431 1,946 7 17,485 16,465 Operating profit 7,009 1,946 8,955 8,917 Pension expense — — — (81) Other income, net 266 324 8 590 223 Interest expense (914) — (914) (802) Profit before income taxes 6,361 2,270 8,631 8,257 Income tax expense 1,108 518 9 1,626 2,912 Net earnings 5,253 1,752 7,005 5,345 Less: Net earnings attributable to the non-controlling interest 52 — 52 139 Net earnings attributable to Kewaunee Scientific Corporation $ 5,201 $ 1,752 $ 6,953 $ 5,206 Net earnings per share attributable to Kewaunee Scientific Corporation stockholders Basic $ 1.82 $ 0.61 $ 2.43 $ 1.81 Diluted $ 1.75 $ 0.59 $ 2.34 $ 1.79 ______________________________ 4 Professional fees incurred during the three months ended October 31, 2024 related to the Company's acquisition of Nu Aire 5 Cost incurred related to the early termination of the Company's Revolving Credit Facility 6 Estimated tax impact of professional and other fees incurred during the three months ended October 31, 2024 related to the Company's acquisition of Nu Aire 7 Professional fees incurred during the six months ended October 31, 2024 related to the Company's acquisition of Nu Aire 8 Cost incurred related to the early termination of the Company's Revolving Credit Facility 9 Estimated tax impact of professional and other fees incurred during the six months ended October 31, 2024 related to the Company's acquisition of Nu Aire About Non-GAAP Measures The Company includes non-GAAP financial measures such as adjusted net earnings and adjusted net earnings per share, in the information provided with this press release as supplemental information relating to its operating results. Adjusted net earnings represents GAAP net earnings adjusted for professional and other fees related to the acquisition of Nu Aire, Inc. and the corresponding tax impact. This financial information is not in accordance with, or an alternative for, GAAP-compliant financial information and may be different from the operating or non-GAAP financial information used by other companies. The Company believes that this presentation of adjusted net earnings and adjusted net earnings per share provides useful information to investors regarding certain additional financial and business trends relating to its financial condition and results of operations. EBITDA and Segment EBITDA are calculated as net earnings (loss), less interest expense and interest income, income taxes, depreciation, and amortization. Adjusted EBITDA and Adjusted Segment EBITDA are calculated as EBITDA or Segment EBITDA less the impact of the professional and other fees related to the Company's acquisition of Nu Aire, Inc., as discussed in more detail above. We believe EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA allow management and investors to compare our performance to other companies on a consistent basis without regard to depreciation and amortization or the professional fees not related to our core business incurred during the current period, which can vary significantly between companies depending upon many factors. EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA are not calculations based upon generally accepted accounting principles, and the method for calculating EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA can vary among companies. The amounts included in the EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA calculations, however, are derived from amounts included in the historical consolidated statements of operations. EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA should not be considered as alternatives to net earnings (loss) or operating earnings (loss) as an indicator of the Company's operating performance, or as an alternative to operating cash flows as a measure of liquidity. About Nu Aire Founded in 1971 and based in Minneapolis , the Company is a leading manufacturer of equipment for a diverse range of laboratory and pharmacy environments. Nu Aire is the North American market share leader in biological safety cabinets and other airflow products and also offers a complete line of CO2 incubators, ultralow freezers, animal handling equipment, pharmacy compounding isolators, and parts and accessories. Nu Aire's equipment is required for safety and quality in every type of laboratory: life sciences research, clinical, hospital, biotech and pharmaceutical R&D, academia, food and beverage, industrial and more. Nu Aire's website is located at http://www.nuaire.com/ . About Kewaunee Scientific Founded in 1906, Kewaunee Scientific Corporation is a recognized global leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products. The Company's products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks. The Company's corporate headquarters are located in Statesville, North Carolina . Sales offices are located in the United States , India , Saudi Arabia , and Singapore . Three manufacturing facilities are located in Statesville serving the domestic and international markets, and one manufacturing facility is located in Bangalore, India serving the local, Asian, and African markets. Kewaunee Scientific's website is located at http://www.kewaunee.com . This press release contains statements that the Company believes to be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this press release, including statements regarding the Company's future financial condition, results of operations, business operations and business prospects, are forward-looking statements. Words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "predict," "believe" and similar words, expressions and variations of these words and expressions are intended to identify forward-looking statements. Such forward-looking statements are subject to known and unknown risks, uncertainties, assumptions, and other important factors that could significantly impact results or achievements expressed or implied by such forward-looking statements. Such factors, risks, uncertainties and assumptions include, but are not limited to: our ability to realize the benefits anticipated as a result of the Nu Aire acquisition; competitive and general economic conditions, including disruptions from government mandates, both domestically and internationally, as well as supplier constraints and other supply disruptions; changes in customer demands; technological changes in our operations or in our industry; dependence on customers' required delivery schedules; risks related to fluctuations in the Company's operating results from quarter to quarter; risks related to international operations, including foreign currency fluctuations; changes in the legal and regulatory environment; changes in raw materials and commodity costs; acts of terrorism, war, governmental action, and natural disasters and other Force Majeure events. The cautionary statements made pursuant to the Reform Act herein and elsewhere by us should not be construed as exhaustive. We cannot always predict what factors would cause actual results to differ materially from those indicated by the forward-looking statements. Over time, our actual results, performance, or achievements will likely differ from the anticipated results, performance or achievements that are expressed or implied by our forward-looking statements, and such difference might be significant and harmful to our stockholders' interest. Many important factors that could cause such a difference are described under the caption "Risk Factors," in Item 1A of our Annual Report on Form 10-K for the fiscal year ended April 30, 2024 , which you should review carefully, and in our subsequent quarterly reports on Form 10-Q and current reports on Form 8-K. These reports are available on our investor relations website at www.kewaunee.com and on the SEC website at www.sec.gov . These forward-looking statements speak only as of the date of this document. The Company assumes no obligation, and expressly disclaims any obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise. Kewaunee Scientific Corporation Condensed Consolidated Statements of Operations (Unaudited) ($ and shares in thousands, except per share amounts) Three Months Ended October 31, Six Months Ended October 31, 2024 2023 2024 2023 Net sales $ 47,764 $ 50,436 $ 96,157 $ 100,275 Cost of products sold 33,812 36,968 69,717 74,893 Gross profit 13,952 13,468 26,440 25,382 Operating expenses 9,518 8,359 19,431 16,465 Operating profit 4,434 5,109 7,009 8,917 Pension expense — (40) — (81) Other (expense) income, net (61) 148 266 223 Interest expense (442) (372) (914) (802) Profit before income taxes 3,931 4,845 6,361 8,257 Income tax expense 916 2,015 1,108 2,912 Net earnings 3,015 2,830 5,253 5,345 Less: Net earnings attributable to the non-controlling interest 7 98 52 139 Net earnings attributable to Kewaunee Scientific Corporation $ 3,008 $ 2,732 $ 5,201 $ 5,206 Net earnings per share attributable to Kewaunee Scientific Corporation stockholders Basic $ 1.05 $ 0.94 $ 1.82 $ 1.81 Diluted $ 1.01 $ 0.93 $ 1.75 $ 1.79 Weighted average number of common shares outstanding Basic 2,872 2,903 2,861 2,882 Diluted 2,974 2,931 2,971 2,908 Kewaunee Scientific Corporation Condensed Consolidated Balance Sheets ($ in thousands) October 31, 2024 April 30, 2024 (Unaudited) Assets Cash and cash equivalents $ 25,963 $ 23,267 Restricted cash 3,701 2,671 Receivables, less allowances 41,885 45,064 Inventories 18,659 20,679 Prepaid expenses and other current assets 6,228 5,136 Total Current Assets 96,436 96,817 Net Property, Plant and Equipment 16,990 17,649 Right of use assets 6,941 7,454 Deferred income taxes 8,305 7,401 Other assets 5,806 5,445 Total Assets $ 134,478 $ 134,766 Liabilities and Stockholders' Equity Short-term borrowings $ 805 $ 3,099 Current portion of lease obligations 2,221 2,234 Current portion of financing liability 750 713 Accounts payable 21,458 23,262 Other current liabilities 11,237 11,472 Total Current Liabilities 36,471 40,780 Long-term portion of lease obligations 5,191 5,669 Long-term portion of financing liability 27,032 27,420 Other non-current liabilities 5,127 4,688 Total Liabilities 73,821 78,557 Kewaunee Scientific Corporation Equity 59,328 54,760 Non-controlling interest 1,329 1,449 Total Stockholders' Equity 60,657 56,209 Total Liabilities and Stockholders' Equity $ 134,478 $ 134,766 Contact: Donald T. Gardner III 704/871-3274 View original content to download multimedia: https://www.prnewswire.com/news-releases/kewaunee-scientific-reports-results-for-second-quarter-of-fiscal-year-2025-302329479.html SOURCE Kewaunee Scientific Corporation © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

South Korea lifts president's martial law decree after lawmakers reject military rule( MENAFN - EIN Presswire) Clinical Communication And Collaboration Software Global market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033 The Business Research Company's Early Year-End Sale! Get up to 30% off detailed market research reports-for a limited time only! LONDON, GREATER LONDON, UNITED KINGDOM, December 13, 2024 /EINPresswire / -- The Business Research Company's Early Year-End Sale! Get up to 30% off detailed market research reports-limited time only! How Has The Clinical Communication And Collaboration Software Market Grown Recently? The clinical communication and collaboration software market size has grown rapidly in recent years. It has increased from $1.64 billion in 2023 to $1.94 billion in 2024 at a compound annual growth rate CAGR of 18.5%. The growth during this historical period can be attributed to growing investments in healthcare IT, the adoption of mobile health mHealth solutions, the rise of telemedicine and virtual care, the growing focus on patient-centric care, and the demand for secure and compliant solutions. Discover Key Insights and Market Trends with a Free Sample Report of the Global Clinical Communication And Collaboration Software Market: What is the Forecasted Growth and Size of the Clinical Communication And Collaboration Software Market? The clinical communication and collaboration software market size is expected to see rapid growth in the next few years. This market will surge to $3.84 billion in 2028 at a compound annual growth rate CAGR of 18.6%. The growth during the forecast period can be attributed to increasing adoption of smart technologies in the healthcare sector, rising demand for cloud-based storage, growing instances of diseases like cancer, cardiovascular ailments, and diabetes, increasing focus on patient-centric care, and rising healthcare spending. What are the Key Drivers Leading to the Rise of the Clinical Communication And Collaboration Software Market? The rising adoption of digital technologies is expected to propel the growth of the clinical communication and collaboration software markets going forward. Digital technologies encompass electronic tools and systems that manage, store, or process data, such as computers, mobile devices or applications, cloud computing, and artificial intelligence AI. The increase in digital technology adoption is largely driven by businesses' need to boost efficiency and maintain competitiveness. These technologies allow businesses to streamline operations and make more effective decisions. Digital technologies enhance clinical communication and collaboration software by enabling instant data sharing, integrating multiple digital platforms, and improving patient information management, thereby benefiting healthcare professionals in better coordination and patient care enhancement. Pre-book the report for a swift delivery: Who are the Major Players in the Clinical Communication And Collaboration Software Market? Key companies operating in the clinical communication and collaboration software market include Microsoft Corporation, Oracle Corporation, Hill-Rom Holdings Inc., Everbridge Inc., Ascom Holding AG, Vocera Communications Inc., Spok Holdings Inc., Imprivata Inc., Symplr, PerfectServe Inc., QliqSOFT Inc., Voalte Inc., Agnity Inc., Telmediq Inc., AMTELCO, PatientSafe Solutions Inc., OnPage Corporation, TigerConnect Inc., NHSmail, Pulsara Inc., Mobile Heartbeat Inc. What Emerging Trends are Impacting the Clinical Communication And Collaboration Software Market? Major companies operating in the clinical communication and collaboration software market are focusing on developing platforms for patient monitoring, community care, and augmented reality. These advancements aim to enhance real-time care delivery and improve healthcare outcomes. How is the Clinical Communication And Collaboration Software Market Segmented? The clinical communication and collaboration software market covered in this report is segmented as follows: 1 By Type: Cloud Based, Web Based 2 By Functionality: Secure Messaging, Medical Alerts And Alarms, Mobile Health Integration 3 By Application: Clinical Workflows, Administrative Workflows 4 By End User: Hospitals, Clinics And Ambulatory Settings, Long-Term Care Facilities What are the Regional Insights of the Clinical Communication And Collaboration Software Market? North America was the largest region in the clinical communication and collaboration software market in 2023. On the other hand, Asia-Pacific is expected to be the fastest-growing region during the forecast period. The regions covered in the clinical communication and collaboration software market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. Browse more similar reports- Clinical Oncology Next Generation Sequencing Global Market Report 2024 Cancer Clinical Decision Tools Global Market Report 2024 Clinical Nutrition Global Market Report 2024 About The Business Research Company Learn More About The Business Research Company. With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game. Contact us at: The Business Research Company: Americas +1 3156230293 Asia +44 2071930708 Europe +44 2071930708 Email us at ... Follow us on: LinkedIn: YouTube: Global Market Model: global-market-model Oliver Guirdham The Business Research Company +44 20 7193 0708 email us here Visit us on social media: Facebook X LinkedIn Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above. MENAFN12122024003118003196ID1108988705 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.ATLANTA, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Oxford Industries, Inc. (NYSE:OXM) today announced financial results for its third quarter of fiscal 2024 ended November 2, 2024. Consolidated net sales in the third quarter of fiscal 2024 were $308 million compared to $327 million in the third quarter of fiscal 2023. Loss per share on a GAAP basis was $0.25 compared to net earnings per share of $0.68 in the third quarter of fiscal 2023. On an adjusted basis, loss per share was $0.11 compared to net earnings per share of $1.01 in the third quarter of fiscal 2023. Tom Chubb, Chairman and CEO, commented, “Following a difficult third quarter, we are pleased with the beginning of the holiday season now that some recent headwinds have started to abate. The cumulative effects of several years of high inflation combined with distractions from the U.S. elections and other world events, led to less frequent and more tentative consumer spending behavior during the third quarter which is traditionally our smallest volume quarter of the year. Additionally, our most significant and important market, the Southeastern United States, was impacted by two major hurricanes in quick succession that resulted in estimated lost sales of $4 million and an estimated impact of $0.14 per share. When combined with a highly competitive and promotional environment, these headwinds led to financial performance that was weaker than expected.” Mr. Chubb concluded, “Encouragingly, consumers have responded favorably to our recent product introductions and marketing campaigns, driving a nice improvement in comp store trends once the holiday season got underway. However, due to the weaker than expected consumer environment before the election and the fourth quarter impact of the hurricanes, which we project will include an additional $3 million of lost revenue and $0.11 per share, we have lowered our fiscal 2024 sales and EPS guidance. We are confident that our business model will drive profitable growth and long-term shareholder value well into the future. We could not do this without our exceptional team of people, to whom we extend our sincere gratitude.” Third Quarter of Fiscal 2024 versus Fiscal 2023 Consolidated net sales of $308 million decreased compared to sales of $327 million in the third quarter of fiscal 2023. Full-price direct-to-consumer (DTC) sales decreased 8% to $200 million versus the third quarter of fiscal 2023. Full-price retail sales of $99 million were 6% lower than prior-year period. E-commerce sales of $101 million were 11% lower than prior-year period. Outlet sales of $17 million were 3% higher than prior-year period. Food and beverage sales were $24 million, a 4% increase versus prior-year period. Wholesale sales of $67 million were 2% lower than the third quarter of fiscal 2023. Gross margin was 63.1% on a GAAP basis, compared to 62.9% in the third quarter of fiscal 2023. The increase in gross margin was primarily due to a $4 million lower LIFO accounting charge and lower discounts at Lilly Pulitzer. This was partially offset due to full-price retail and e-commerce sales representing a lower proportion of net sales at Tommy Bahama, Lilly Pulitzer and Johnny Was with more sales occurring during promotional and clearance events. Adjusted gross margin, which excludes the effect of LIFO accounting, decreased to 63.0% compared to 64.0% on an adjusted basis in the prior-year period. SG&A was $205 million compared to $195 million last year. On an adjusted basis, SG&A was $201 million compared to $191 million in the prior-year period. The increase in SG&A was primarily driven by: Expenses related to 33 new store openings since the third quarter of fiscal 2023, including four Tommy Bahama Marlin Bars. Pre-opening expenses related to approximately five additional stores planned to open in the fourth quarter of fiscal 2024, including two additional Tommy Bahama Marlin Bars that are expected to open in the next few months. The addition of Jack Rogers. Royalties and other operating income of $4 million were comparable to the third quarter of fiscal 2023. Operating loss was $6 million, or (2.0%) of net sales, compared to operating income of $14 million, or 4.4% of net sales, in the third quarter of fiscal 2023. On an adjusted basis, operating income decreased to an operating loss of $3 million, or (1.1%) of net sales, compared to operating income of $21 million, or 6.6% of net sales, in the third quarter of fiscal 2023. The decreased operating income includes the impact of decreased net sales and increased SG&A as the Company continues to invest in the business. Interest expense decreased from $1 million in the prior year period. The decreased interest expense was primarily due to a lower average outstanding debt balance during the third quarter of fiscal 2024 than the third quarter of fiscal 2023. Due to lower earnings during the third quarter as compared to our other fiscal quarters, certain discrete or other items have a more pronounced impact on the effective tax rate. Our effective income tax rate of 42.5% for the third quarter of fiscal 2024 included the impact of discrete, favorable US federal return-to-provision adjustments primarily related to an increase in the research and development tax credit and certain adjustments to the US taxation on foreign earnings. For the third quarter of fiscal 2023, our effective income tax rate of 18.6% included the favorable utilization of the research and development tax credit and adjustments to the US taxation on foreign earnings which reduced the effective tax rate. Balance Sheet and Liquidity Inventory decreased $3 million, or 2%, on a LIFO basis and increased $2 million, or 1%, on a FIFO basis compared to the end of the third quarter of fiscal 2023. Inventory balances were comparable in all operating groups. During the first nine months of fiscal 2024, cash flow from operations was $104 million compared to $169 million in the first nine months of fiscal 2023. The cash flow from operations in the first nine months of fiscal 2024, along with borrowings of $29 million, provided sufficient cash to fund $92 million of capital expenditures and $33 million of dividends. During the third quarter of fiscal 2024, long-term debt decreased to $58 million compared to $66 million of borrowings outstanding at the end of the third quarter of fiscal 2023 as cash flow from operations exceeded increased capital expenditures primarily associated with the project to build a new distribution center in Lyons, Georgia, payments of dividends and working capital requirements. The Company had $7 million of cash and cash equivalents versus $8 million of cash and cash equivalents at the end of the third quarter of fiscal 2023. Dividend The Board of Directors declared a quarterly cash dividend of $0.67 per share. The dividend is payable on January 31, 2025 to shareholders of record as of the close of business on January 17, 2025. The Company has paid dividends every quarter since it became publicly owned in 1960. Outlook For fiscal 2024 ending on February 1, 2025, the Company revised its sales and EPS guidance. The Company now expects net sales in a range of $1.50 billion to $1.52 billion as compared to net sales of $1.57 billion in fiscal 2023. In fiscal 2024, GAAP EPS is expected to be between $5.78 and $5.98 compared to fiscal 2023 GAAP EPS of $3.82. Adjusted EPS is expected to be between $6.50 and $6.70, compared to fiscal 2023 adjusted EPS of $10.15. For the fourth quarter of fiscal 2024, the Company expects net sales to be between $375 million and $395 million compared to net sales of $404 million in the fourth quarter of fiscal 2023. GAAP EPS is expected to be between $1.02 and $1.22 in the fourth quarter compared to a GAAP loss per share of $3.85 in the fourth quarter of fiscal 2023 that included noncash impairment charges totaling $114 million, or $5.31 per share. Adjusted EPS is expected to be between $1.18 and $1.38 compared to adjusted EPS of $1.90 in the fourth quarter of fiscal 2023. The Company anticipates interest expense of $3 million in fiscal 2024, with interest expense expected to be $1 million in the fourth quarter of fiscal 2024. The Company’s effective tax rate is expected to be approximately 23% for the full year of fiscal 2024. Capital expenditures in fiscal 2024, including the $92 million in the first nine months of fiscal 2024, are expected to be approximately $150 million compared to $74 million in fiscal 2023. The planned year-over-year increase in capital expenditures includes approximately $75 million now budgeted in fiscal 2024 for the distribution center project in Lyons, Georgia. Additionally, we have been investing in new brick and mortar locations, relocations and remodels of existing locations resulting in a year-over-year net increase of full price stores of approximately 30 by the end of fiscal 2024, which includes approximately five planned to open in the fourth quarter of the year. We will also continue with our investments in our various technology systems initiatives, including e-commerce and omnichannel capabilities, data management and analytics, customer data and insights, cybersecurity, automation, including artificial intelligence, and infrastructure. Conference Call The Company will hold a conference call with senior management to discuss its financial results at 4:30 p.m. ET today. A live web cast of the conference call will be available on the Company’s website at www.oxfordinc.com. A replay of the call will be available through December 25, 2024 by dialing (412) 317-6671 access code 13750235. About Oxford Oxford Industries, Inc., a leader in the apparel industry, owns and markets the distinctive Tommy Bahama ® , Lilly Pulitzer ® , Johnny Was®, Southern Tide ® , The Beaufort Bonnet Company ® , Duck Head ® and Jack Rogers ® lifestyle brands. Oxford's stock has traded on the New York Stock Exchange since 1964 under the symbol OXM. For more information, please visit Oxford's website at www.oxfordinc.com. Basis of Presentation All per share information is presented on a diluted basis. Non-GAAP Financial Information The Company reports its consolidated financial statements in accordance with generally accepted accounting principles (GAAP). To supplement these consolidated financial results, management believes that a presentation and discussion of certain financial measures on an adjusted basis, which exclude certain non-operating or discrete gains, charges or other items, may provide a more meaningful basis on which investors may compare the Company’s ongoing results of operations between periods. These measures include adjusted earnings, adjusted earnings per share, adjusted gross profit, adjusted gross margin, adjusted SG&A, and adjusted operating income, among others. Management uses these non-GAAP financial measures in making financial, operational, and planning decisions to evaluate the Company’s ongoing performance. Management also uses these adjusted financial measures to discuss its business with investment and other financial institutions, its board of directors and others. Reconciliations of these adjusted measures to the most directly comparable financial measures calculated in accordance with GAAP are presented in tables included at the end of this release. Safe Harbor This press release includes statements that constitute forward-looking statements within the meaning of the federal securities laws. Generally, the words "believe," "expect," "intend," "estimate," "anticipate," "project," "will" and similar expressions identify forward-looking statements, which generally are not historical in nature. We intend for all forward-looking statements contained herein, in our press releases or on our website, and all subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf, to be covered by the safe harbor provisions for forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Such statements are subject to a number of risks, uncertainties and assumptions including, without limitation, demand for our products, which may be impacted by macroeconomic factors that may impact consumer discretionary spending and pricing levels for apparel and related products, many of which may be impacted by inflationary pressures, elevated interest rates, concerns about the stability of the banking industry or general economic uncertainty, and the effectiveness of measures to mitigate the impact of these factors; possible changes in governmental monetary and fiscal policies, including, but not limited to, Federal Reserve policies in connection with continued inflationary pressures and the impact of the recent elections in the United States; competitive conditions and/or evolving consumer shopping patterns, particularly in a highly promotional retail environment; acquisition activities (such as the acquisition of Johnny Was), including our ability to integrate key functions, recognize anticipated synergies and minimize related disruptions or distractions to our business as a result of these activities; supply chain disruptions; changes in trade policies and regulations, including the potential for increases or changes in duties, current and potentially new tariffs or quotas; costs and availability of labor and freight deliveries, including our ability to appropriately staff our retail stores and food & beverage locations; costs of products as well as the raw materials used in those products, as well as our ability to pass along price increases to consumers; energy costs; our ability to respond to rapidly changing consumer expectations; unseasonal or extreme weather conditions or natural disasters, such as the September and October 2024 hurricanes impacting the Southeastern United States; lack of or insufficient insurance coverage; the ability of business partners, including suppliers, vendors, wholesale customers, licensees, logistics providers and landlords, to meet their obligations to us and/or continue our business relationship to the same degree as they have historically; retention of and disciplined execution by key management and other critical personnel; cybersecurity breaches and ransomware attacks, as well as our and our third party vendors’ ability to properly collect, use, manage and secure business, consumer and employee data and maintain continuity of our information technology systems; the effectiveness of our advertising initiatives in defining, launching and communicating brand-relevant customer experiences; the level of our indebtedness, including the risks associated with heightened interest rates on the debt and the potential impact on our ability to operate and expand our business; the timing of shipments requested by our wholesale customers; fluctuations and volatility in global financial and/or real estate markets; our ability to identify and secure suitable locations for new retail store and food & beverage openings; the timing and cost of retail store and food & beverage location openings and remodels, technology implementations and other capital expenditures; the timing, cost and successful implementation of changes to our distribution network; the effectiveness of recent, focused efforts to reassess and realign our operating costs in light of revenue trends, including potential disruptions to our operations as a result of these efforts; pandemics or other public health crises; expected outcomes of pending or potential litigation and regulatory actions; the increased consumer, employee and regulatory focus on sustainability issues and practices, including failures by our suppliers to adhere to our vendor code of conduct; the regulation or prohibition of goods sourced, or containing raw materials or components, from certain regions and our ability to evidence compliance; access to capital and/or credit markets; factors that could affect our consolidated effective tax rate; the risk of impairment to goodwill and other intangible assets such as the recent impairment charges incurred in our Johnny Was segment; and geopolitical risks, including ongoing challenges between the United States and China and those related to the ongoing war in Ukraine, the Israel-Hamas war and the conflict in the Red Sea region. Forward-looking statements reflect our expectations at the time such forward-looking statements are made, based on information available at such time, and are not guarantees of performance. Although we believe that the expectations reflected in such forward-looking statements are reasonable, these expectations could prove inaccurate as such statements involve risks and uncertainties, many of which are beyond our ability to control or predict. Should one or more of these risks or uncertainties, or other risks or uncertainties not currently known to us or that we currently deem to be immaterial, materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, estimated or projected. Important factors relating to these risks and uncertainties include, but are not limited to, those described in Part I. Item 1A. Risk Factors contained in our Fiscal 2023 Form 10-K, and those described from time to time in our future reports filed with the SEC. We caution that one should not place undue reliance on forward-looking statements, which speak only as of the date on which they are made. We disclaim any intention, obligation or duty to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

None

SmartDrone Corporation Black Primary Logo Skytec Black Primary Logo SmartDrone Corporation Black Primary Logo Skytec Black Primary Logo TYLER, Texas , Dec. 3, 2024 /PRNewswire/ -- SmartDrone Corporation, "The U.S.A. Drone Company" ® , is excited to announce the acquisition of the drone operations of Skytec, LLC, a Chattanooga -based leader in remote sensing and GIS technology. This acquisition allows SmartDrone to expand its UAV service offerings while continuing to support Skytec's clients with high-precision aerial data collection across industries, including landsurveying, construction, and environmental management.UConn F Alex Karaban (head) won't play vs. Baylor

PLAINVIEW, N.Y., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Veeco Instruments Inc. (NASDAQ: VECO) today announced that management is scheduled to participate in the following investor events: About Veeco Veeco (NASDAQ: VECO) is an innovative manufacturer of semiconductor process equipment. Our laser annealing, ion beam, chemical vapor deposition (CVD), metal organic chemical vapor deposition (MOCVD), single wafer etch & clean and lithography technologies play an integral role in the fabrication and packaging of advanced semiconductor devices. With equipment designed to optimize performance, yield and cost of ownership, Veeco holds leading technology positions in the markets we serve. To learn more about Veeco's systems and service offerings, visit www.veeco.com . To the extent that this news release discusses expectations or otherwise makes statements about the future, such statements are forward-looking and are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include the risks discussed in the Business Description and Management's Discussion and Analysis sections of Veeco's Annual Report on Form 10-K for the year ended December 31, 2023 and in our subsequent quarterly reports on Form 10-Q, current reports on Form 8-K and press releases. Veeco does not undertake any obligation to update any forward-looking statements to reflect future events or circumstances after the date of such statements. Veeco Contacts: Investors: Anthony Pappone | (516) 500-8798 | [email protected] Media: Brenden Wright | (410) 984-2610 | [email protected]METAIRIE, La. (AP) — Dejounte Murray plans to return to the New Orleans Pelicans ' lineup on Wednesday night for the first time since fracturing his left hand in a season-opening victory over Chicago on Oct. 23. And when Murray takes the court against the Toronto Raptors , his mother will be on his mind. After practice on Tuesday, Murray discussed his impending return and disclosed more details about the previously unspecified “personal matters” that caused him to leave the team during the final days of the preseason. His mother had a stroke, he said. “It was tough to leave and go deal with that. As she got better, she wanted me to come play,” Murray said of his last-minute decision to start against Chicago. He added that his hand injury near the end of that game was God's way of telling him, “‘Nah, you need to stay with your mom.’” “I was more concerned about my mother. That was my priority,” Murray continued. “I wasn’t really worried about my recovery.” Murray's mother has recovered well, he said, while he is “healthy and ready to help this team.” “I’m ready to hoop. Play for my mother — she’s going to be watching," Murray said. “I’m ready to compete, bring that winning spirit.” The Pelicans (4-14) certainly could use the help, having lost 14 of 16 games since opening the season with a pair of victories. Injuries have ravaged the roster. At times, all five starters have been out. Star power forward Zion Williamson has missed 12 games this season — one with an illness and 11 with a hamstring injury. Herb Jones has been sidelined by a shoulder strain and Brandon Ingram's status is in doubt after he sat out practice on Tuesday with calf soreness that also sidelined him during a loss on Monday night at Indiana. But at least two starters — Murray and fellow guard CJ McCollum — are expected to play against the Raptors. “I don’t care how many games we’ve lost. I just know every time I step on the floor I feel like we can win games,” said Murray, who had 14 points, 10 assists and eight rebounds in his lone game with the Pelicans. "That’s just my mentality, and I feel like it can carry over to a lot of guys.” AP NBA: https://apnews.com/hub/NBA

Tech review: Gift options for the cord cutter

Every December, as it has since 1927 with Charles Lindbergh, Time magazine selects and features the most consequential Person of the Year (13 United States presidents, other world leaders, popes). Sometimes it has not been a person, as such, but a tectonic societal shift (the personal computer, the #MeToo movement). Donald Trump, just named Time’s 2024 Person of the Year , was first elevated to that title after his 2016 election victory. He is consequential because he has returned to power even after attempting to overturn the results of the 2020 presidential election, even after supporting the insurrection on January 6, 2021, and notwithstanding being twice impeached and convicted of a felony. President-elect Donald Trump speaks during Time magazine’s Person of the Year announcement at the New York Stock Exchange. Credit: AP This year, no one else was on so many people’s minds as Trump. In Time’s judgment , Trump was “the person who had the greatest influence, for better or worse, on the events of the year”. Time might have conferred the accolade jointly on Trump and Elon Musk, given Musk’s astonishing fusion of more than $US250 million in campaign contributions with his dominance over his X platform to help make Trump president. If influence is power, Musk has it. With ceaseless hours at Trump’s side to help shape his presidency, and his establishment and funding of a Musk think tank that will generate edicts for Trump to impose to re-sculpt the government, Musk has effectively supplanted JD Vance to become Trump’s vice president. Musk’s power is second only to Trump’s. For the next two years, Trump will be at his zenith. He will never have to face the voters again, which means he can act with impunity as he makes decisions to advance Trumpism and all that he wants to accomplish. Trump’s Republican Party, which he now owns, controls both houses of Congress, so there will be no more impeachments. His attorney-general and chief of the FBI will go after his political enemies . His secretary of defence will ensure that his generals follow his orders – overseas and in the streets of America’s cities. Loading Public servants will take loyalty oaths or be purged. Trump will take money appropriated by the Congress away from programs he does not like and divert it to his priorities. On the world stage, Trump will present more like Putin, Xi and Orban than Starmer, Macron and Albanese. Trump has already broken the norm of the US having “one president at a time” with his pre-inaugural threats to Mexico, Canada and China on trade and his forays into concluding the wars in Ukraine and the Middle East on his terms. His first inaugural address eight years ago featured the dystopian theme of “American carnage”. We will see how deep he wallows in that dark pool on January 20, 2025. Immediately after his address, when he arrives in the Oval Office, Trump’s march through the first 100 days will formally begin. Political newsletter Axios reports that “Trump advisers are running out of words to describe what’s coming in January”. “They say he feels empowered and emboldened, vindicated and validated, and eager to stretch the boundaries of power.” Trump will sign dozens of executive orders repealing everything he can that Biden did with his executive démarches four years ago, such as on climate, abortion rights, immigration, gun control and student loans. Loading Trump’s nominees will face confirmation hearings and votes in the Senate. There will be firestorms around Kash Patel to head the FBI, who wants to close the FBI’s building, expel its agents around the country and prosecute Trump’s enemies; Robert Kennedy Jr as secretary of health and human services, who wants to take a baseball bat to how Anthony Fauci practises medicine, but is opposed by 75 Nobel laureates ; Pete Hegseth at Defence, under fire for sexual misconduct, alcohol abuse and financial mismanagement; and Tulsi Gabbard as director of national intelligence, who many see as an asset to Putin. Any who are knocked back will be replaced by other loyal Trumpists with the same mandates. They will do all that Trump wants. Trump will move to pardon and release from jail hundreds of his foot soldiers who stormed the Capitol on January 6. After Biden’s pardon of his son Hunter, Trump will not even be singed by the critics. Trump will begin the detention and process of deporting hundreds of thousands of immigrants across the country. He will unveil legislation to get his budget, close the borders, cut taxes and fight over the public debt limit to avoid a default of the United States. Loading Trump will begin to implement his campaign promises – over and above the threats against Mexico, Canada and China – to impose across-the-board tariffs of up to 20 per cent on all goods coming into the US and up to 60 per cent for imports from China. Will Australia be in these crosshairs? There is absolutely no basis on which Trump’s tariffs on Australia can be justified. Trump loves a trade surplus. Australia has a structural trade deficit with the US. Australia has a free trade agreement with the US. New higher tariffs are incompatible with the letter and spirit of that trade pact. But there is a real threat here. Trump has just ripped up the trade agreement he negotiated in his first term with Canada and Mexico. If Trump can do that to those allies he can do it to Australia. This could be the first hard test in the Australia-US, Albanese-Trump relationship. Trump – let’s call him Person of the Century, so far – is on a high. The year ahead will be savage. The waves of Trump’s first 100 days will hit Australia’s shores too. Bruce Wolpe is a senior fellow at the University of Sydney’s United States Studies Centre. He has served on the Democratic staff in the US Congress and as chief of staff to former prime minister Julia Gillard. Save Log in , register or subscribe to save articles for later. License this article Trump's America Opinion Trump diplomacy Donald Trump Elon Musk FBI More... Bruce Wolpe is a senior fellow at the University of Sydney's United States Studies Centre. He has served on the Democratic staff in the US Congress and as chief of staff to former prime minister Julia Gillard. Most Viewed in World LoadingMANCHESTER, England (AP) — Manchester City manager Pep Guardiola denied he has a “personal problem” with Kevin De Bruyne and insisted Tuesday the playmaker's absence from the team in recent weeks was down to his fitness issues. City has not won in seven games in all competitions — its worst run under Guardiola — and De Bruyne has featured only as a substitute in the last five of those matches after recovering from a pelvic injury. The Belgium midfielder was injured during City’s Champions League match with Inter Milan on Sept. 18 and hasn't started since. A number of prominent pundits, including former City defender and club ambassador Micah Richards, have questioned why De Bruyne has not been starting games amid the champions’ dramatic slump. Richards said on “The Rest is Football” podcast that it appeared “there’s some sort of rift going on” between De Bruyne and Guardiola. Guardiola responded in his news conference ahead of Wednesday's Premier League match against Nottingham Forest, saying: “People say I’ve got a problem with Kevin. Do you think I like to not play with Kevin? No, I don’t want Kevin to play? “The guy who has the most talent in the final third — I don’t want it? I have a personal problem with him after nine years together? He’s delivered to me the biggest success to this club, but he’s been five months injured (last season) and two months injured (this year). He’s 33 years old. He needs time to find his best, like last season, step by step. He’ll try to do it and feel better. I’m desperate to have his best.” Both De Bruyne and Guardiola have spoken since of the pain De Bruyne was in after his injury against Inter and the need to ease him back into action. De Bruyne is in the final year of his contract. “I’d love to have the Kevin in his prime, 26 or 27. He would love it too — but he is not 26 or 27 anymore," Guardiola said. “He had injuries in the past, important and long ones. He is a guy who needs to be physically fit for his space and energy. You think I’m complaining? It’s normal, it’s nature. He’s played in 10 or 11 seasons a lot of games and I know he is desperate to help us. He gives glimpses of brilliance that only he can have." AP soccer: https://apnews.com/hub/soccerLight & Wonder, Inc. Announcement: If You Have Suffered Losses in Light & Wonder, Inc. ...